首页> 美国卫生研究院文献>BMC Genomics >Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility
【2h】

Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility

机译:阐明结核分枝杆菌吡嗪酰胺酶酶Lys96突变与吡嗪酰胺敏感性之间关系的机理分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPyrazinamide (PZA) is one of the most effective first line treatments against tuberculosis disease. The drug generally has bacteriostatic action. It also acts on bacterial spores which eliminates the chances of resurfacing of the infection. However, in recent years there has been a major increase in the occurrence of drug resistant bacterial strains. Resistance against PZA is caused by mutations in pyrazinamidase (PncA) protein which is the activator of the prodrug PZA. In the present study, we have tried to gain insights into the mechanism by which resistance develops due to K96R mutation occurring in the PncA catalytic region
机译:背景吡嗪酰胺(PZA)是抗结核病最有效的一线治疗方法之一。该药物通常具有抑菌作用。它也作用于细菌孢子,从而消除了感染重新出现的机会。但是,近年来,耐药菌菌株的发生已大大增加。对PZA的抗性是由吡嗪酰胺酶(PncA)蛋白的突变引起的,该蛋白是前药PZA的激活剂。在本研究中,我们试图深入了解由于PncA催化区域中发生的K96R突变而产生耐药性的机制

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号